Nano-liposome protective agent with anti-ultraviolet and anti-oxidation functions, preparation method, preparation and application of nano-liposome protective agent

By using specific components and treatment methods in nanoliposomes, their anti-UV and anti-oxidation functions are enhanced, and the problems of easy oxidation and insufficient stability of nanoliposomes are solved, and the retention rate and transdermal performance of active ingredients are improved. .

CN118986777AActive Publication Date: 2024-11-22GUANGZHOU PREXIN BIOTECHNOLOGY CO LTD

Patent Information

Application Number
CN202411197138.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-29
Publication Date
2024-11-22
Estimated Expiration
2044-08-29

AI Technical Summary

Technical Problem

Existing nanoliposomes are easily oxidized when isolated from air and lack the anti-ultraviolet and anti-oxidation functions, resulting in poor stability of active ingredients and transdermal effect.

Method used

Use benzotriazolyldodecylp-cresol/benzotriazolylbutylphenolsulfonate, tris(tetramethylhydroxypiperidol) citrate, tracrutin/rutin and pentaerythritol tetrahydrin Components such as (bis-tert-butylhydroxyhydrogenated cinnamic acid) ester/tocopherol acetate are used as nanoliposome protectors. Through homogenization and microjet homogenization treatment, the nanoliposomes can be enhanced to enhance the anti-UV and anti-oxidation of nanoliposomes through homogenization and microjet homogenization treatment. Function.

Benefits of technology

It effectively reduces the loss of ultraviolet rays and oxygen on active ingredients during storage and shelf, extends the shelf life, improves the retention rate and transdermal performance of active ingredients, and enhances the stability and effect of nanoliposomes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118986777A_ABST
    Figure CN118986777A_ABST
Patent Text Reader

Abstract

The invention provides a nano-liposome protective agent with anti-ultraviolet and anti-oxidation functions, a preparation method, a preparation and application of the nano-liposome protective agent, and relates to the technical field of cosmetics. The nano-liposome protective agent is prepared from the following components: benzotriazolyl dodecyl p-cresol / benzotriazolyl butyl sodium phenolsulfonate, tri (tetramethyl hydroxypiperidinol) citrate, troxerutin / rutin and pentaerythritol tetra (bis-tert-butyl hydroxyhydrocinnamic acid) ester / tocopheryl acetate. The nano-liposome protective agent has anti-ultraviolet and anti-oxidation activity at the same time, when the nano-liposome protective agent is added into the nano-liposome, the loss of the activity of the functional components and the loss of a nano-liposome phospholipid membrane material caused by ultraviolet rays and oxygen during storage and shelf life can be effectively reduced, and the effects of prolonging the shelf life, improving the curative effect and promoting the transdermal permeability of the nano-liposome are achieved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of cosmetics, and specifically to a nanoliposome protective agent with anti-ultraviolet and anti-oxidation functions, a preparation method, a preparation and application thereof. Background Art

[0002] The role of nanoliposomes in the cosmetics field can be summarized as: improving the solubility properties of active ingredients, protecting labile active ingredients, improving transdermal effects, controlling the penetration rate of active ingredients and reducing their irritation, thereby improving the permeability of active ingredients, enhancing application synergy and on-site production effectiveness.

[0003] However, the structural layer of nanoliposomes is mostly composed of phospholipids or phosphatidylcholine, which will be oxidized by air and oxygen dissolved in the solution when isolated from the air. At the same time, phospholipids or phosphatidylcholine do not have the ability to isolate the photodecomposition effect of ultraviolet rays on active ingredients and systems and the effect of excited state intensity. Chinese invention patent application CN112006924A discloses a chitosan-modified multivitamin nanoliposome and its preparation method and application in cosmetics. In order to overcome the shortcomings and deficiencies of oxidative rancidity and sudden release of multivitamin nanoliposomes in the prior art, a double-layer wrapping method is adopted, that is, a layer of chitosan coating is wrapped on the outside of the liposome, which maximizes the solution to the problem of oxidative rancidity and sudden release of multivitamins in the liposome, and further improves the stability of the product. Non-patent literature "Modification and stability study of mulberry anthocyanin nanoliposomes [J]" (Chang Ying, Yang Xiaoxue, Jiao Yan, et al. Food Science and Technology, 2020, 45 (12): 251-257. DOI:10.13684 / j.cnki.spkj.2020.12.038.) In the study, compared with unmodified liposomes, chitosan-modified anthocyanin nanoliposomes can reduce the degradation and loss of anthocyanins under light, heat and metal ion conditions, which helps to enhance the structural stability of mulberry anthocyanins and thus exert their effective biological activity, but the anti-ultraviolet and antioxidant functions of the nanoliposome encapsulation system need to be further improved.

[0004] There are nearly 30 chemical UV absorbers allowed for use in the "Technical Specifications for Safety of Cosmetics" (2015 edition), and there are even more inorganic UV absorbers. However, the photostability of some UV absorbers is relatively poor, and isomerization is an important factor in the instability of some UV absorbers. Photoinduced degradation not only reduces the desired UV protection effect of some UV absorbers, but also may produce harmful photolysis products. Preventing the oxidation of active ingredients and phospholipids is the basic requirement for building an antioxidant system, and antioxidants are the most effective form for the system to exert antioxidant effects. From the perspective of efficacy and safety, UV absorbers and antioxidants must have high stability and significant efficacy. Therefore, it is very necessary to develop a type of protective agent with anti-ultraviolet and antioxidant functions for the nanoliposome encapsulation system. Summary of the invention

[0005] The present invention aims at the problems existing in the prior art and provides a nanoliposome protective agent with anti-ultraviolet and anti-oxidation functions, a preparation method, a preparation and an application thereof. The components of the nanoliposome protective agent include benzotriazolyl dodecyl p-cresol / benzotriazolyl butylphenol sodium sulfonate, tris (tetramethylhydroxypiperidinol) citrate, troxerutin / rutin and pentaerythritol tetra (di-tert-butyl hydroxyhydrocinnamate) ester / tocopherol acetate. The nanoliposome protective agent is added to the nanoliposome, which can effectively reduce the loss of ultraviolet and oxygen on the activity of the functional components and the phospholipid membrane material of the nanoliposome during storage and shelf life, thereby extending the shelf life, improving the effect and promoting the transdermal permeability of the nanoliposome.

[0006] To achieve the above purpose, the technical solution adopted by the present invention is as follows: The first aspect of the present invention is to provide a nanoliposome protective agent with anti-ultraviolet and anti-oxidation functions, wherein the nanoliposome protective agent comprises the following components: benzotriazolyl dodecyl p-cresol / benzotriazolyl butylphenol sodium sulfonate, tris (tetramethylhydroxypiperidinol) citrate, troxerutin / rutin and pentaerythritol tetra (di-tert-butyl hydroxyhydrocinnamate) ester / tocopherol acetate.

[0007] Preferably, the components are composed by weight: 0.05-0.2 parts of benzotriazolyl dodecyl p-cresol / benzotriazolyl butylphenol sodium sulfonate, 0.05-0.2 parts of tris(tetramethylhydroxypiperidinol) citrate, 0.15-0.6 parts of troxerutin / rutin and 0.05-0.2 parts of pentaerythritol tetra(di-tert-butylhydroxyhydrocinnamate) ester / tocopherol acetate.

[0008] Further preferably, the components are composed by weight: 0.1 part of benzotriazolyl dodecyl p-cresol / benzotriazolyl butylphenol sodium sulfonate, 0.15 part of tris(tetramethylhydroxypiperidinol) citrate, 0.3 part of troxerutin / rutin and 0.1 part of pentaerythritol tetra(di-tert-butyl hydroxyhydrocinnamate) ester / tocopherol acetate.

[0009] The second aspect of the present invention is to provide a method for preparing the above-mentioned nanoliposome protective agent, which comprises dissolving benzotriazolyl dodecyl p-cresol / benzotriazolyl butylphenol sodium sulfonate, tris (tetramethyl hydroxypiperidinol) citrate, troxerutin / rutin and pentaerythritol tetra (di-tert-butyl hydroxyhydrocinnamate) ester / tocopherol acetate in a propylene glycol solvent and homogenizing to obtain the protective agent.

[0010] Preferably, the homogenization is mixing shear homogenization and / or homogenization by a microfluidizer.

[0011] More preferably, the mixing shear pressure is 12000 rpm-16000 rpm, and the mixing shear homogenization time is 5-15 min.

[0012] Further preferably, the microfluidic homogenization pressure is 12000psi-20000psi, and the homogenization times are 1-3 times.

[0013] The third aspect of the present invention is to provide a nanoliposome preparation containing the above-mentioned nanoliposome protective agent.

[0014] Preferably, the nanoliposome preparation comprises the following preparation steps: (1) dissolving benzotriazolyl dodecyl p-cresol / benzotriazolyl butylphenol sodium sulfonate, tris(tetramethylhydroxypiperidinol) citrate, troxerutin / rutin and pentaerythritol tetra(di-tert-butylhydroxyhydrocinnamate) ester / tocopherol acetate in propylene glycol solvent, homogenizing, and obtaining an alcohol phase; (2) shearing and homogenizing the oil phase and water phase of the liposome and the alcohol phase of step (1) to obtain a mixed colostrum; (3) The colostrum mixture is homogenized once by a microfluidizer to obtain the colostrum.

[0015] Further preferably, in step (2), the weight percentage of the alcohol phase in the nanoliposome preparation is 0.1-0.5%.

[0016] More preferably, the homogenization time in step (2) is 5-15 min, more specifically 10 min.

[0017] Further preferably, the microfluidic homogenization pressure in step (3) is 12000psi-20000psi, and the homogenization times are 1-3 times. More specifically, the microfluidic homogenization pressure is 16000psi, and the homogenization times are 3 times.

[0018] The fourth aspect of the present invention is to provide a use of the above-mentioned nanoliposome protective agent or the nanoliposome protective agent prepared by the above-mentioned preparation method or the nanoliposome preparation containing the above-mentioned nanoliposome protective agent in the preparation of cosmetics with anti-ultraviolet and anti-oxidation functions.

[0019] Compared with the prior art, the present invention has the following beneficial effects: (1) The nanoliposome protective agent provided by the present invention has both anti-ultraviolet and antioxidant activities. During the shelf life, the nanoliposome preparation has a good appearance and morphology, without rancidity or collapse, and the active ingredient retention rate is higher; (2) the transdermal performance of the system is maintained and enhanced, and the effect of the system is enhanced. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 : Transmission electron microscopic morphological observations of the nanoliposome preparation 1 sample on the first day and at 45 °C for 28 days; Figure 2 : Particle size test results of nanoliposome preparation 1 sample on the first day and at 45 °C for 28 days; Figure 3 : Zeta potential diagram of the sample of nanoliposome preparation 1 on the first day and after being placed at 45 °C for 28 days; Figure 4 : Nanoliposome preparation 1 sample stability test results. DETAILED DESCRIPTION

[0021] The following non-limiting examples can enable those skilled in the art to more fully understand the present invention, but do not limit the present invention in any way. The following content is merely an exemplary description of the scope of the present invention, and those skilled in the art can make various changes and modifications to the present invention based on the disclosed content, which should also fall within the scope of the present invention.

[0022] Embodiment 1: The components of the nanoliposome protective agents numbered 1-6 are shown in Table 1.

[0023] Table 1: Components of nanoliposome protective agent (unit: part)

[0024] Embodiment 2: (1) Nanoliposome preparations 1-7 Oil phase composition: 15 parts octyl dodecanol, 6 parts phospholipids, 3 parts polysorbate-80 Water phase composition: 10 parts glycerin, balance water Alcohol phase: 1 part of nanoliposome protective agent numbered 1-6 or no nanoliposome protective agent Active ingredient: 5 parts 4-butylresorcinol Note: The total amount of nanoliposome preparations 1-7 is 100 parts, and the balance is made up with water.

[0025] (2) Nanoliposome preparations 8-14 Oil phase composition: 8 parts phospholipids, 40 parts caprylic / capric triglyceride, 3 parts polysorbate-80 Water phase composition: balance water Alcohol phase: 1 part of nanoliposome protective agent numbered 1-6 or no nanoliposome protective agent Active ingredient: 0.5 parts astaxanthin Note: The total amount of nanoliposome preparations 8-14 is 100 parts, and the balance is made up with water.

[0026] Test Example 1: Property Detection of Nanoliposome Preparation 1 1. Transmission electron microscopy morphology observation Test method: Use Hitachi HT7800 high-contrast transmission electron microscope to observe the surface morphology of the sample. Before analysis, dilute the nanoliposome preparation 1 samples prepared on the 1st day and the 28th day with ultrapure water of pH 7.0 to appropriate concentrations, drop 10 µL of the diluted sample on the copper mesh, let it stand for 2 minutes, absorb the excess sample around the copper mesh, and then use 2.0 wt% uranyl acetate solution to negatively stain the copper mesh for 5 minutes. Remove the excess staining solution with filter paper, dry it naturally at room temperature, take an appropriate amount of sample and drop it on the copper mesh plate, then take pictures and record the data. The results are shown in Figure 1 ,in Figure 1 A in the figure is the transmission electron microscopy morphology observation result of the nanoliposome preparation 1 sample on the first day. Figure 1 B in the figure is the transmission electron microscopy morphological observation result of the nanoliposome preparation 1 sample on the 28th day.

[0027] 2. Particle size, PDI and Zeta potential The average particle size, PDI and Zeta potential of the samples were measured using a Zetasizer Nano ZSE nanoparticle size analyzer. First, the nanoliposome preparation 1 samples prepared on the 1st day and the 28th day were diluted 100 times with ultrapure water, the test temperature was set to 25 °C, the scattering angle was set to 90°, and each sample was scanned 3 times with the average value as the measured value. The results are shown in Figure 2 ,in Figure 2 A in the figure is the average particle size test result of the nanoliposome preparation 1 sample on the first day. Figure 2B in the figure is the average particle size test result of the nanoliposome preparation 1 sample on the 28th day. The specific values ​​are shown in Table 2.

[0028] Table 2: Average particle size test results of nanoliposome preparation 1 samples on day 1 and day 28

[0029] When measuring the Zeta potential, the sample is not diluted and is directly added to the Zeta potential cell for measurement. The results are shown in Figure 3 ,in Figure 3 A in the figure is the Zeta potential test result of the nanoliposome preparation 1 sample on the first day. Figure 3 B in FIG. 2 is the Zeta potential test result of the sample of nanoliposome preparation 1 on day 28. The specific values ​​are shown in Table 3.

[0030] Table 3: Zeta potential test results of nanoliposome preparation 1 samples on day 1 and day 28

[0031] 3. Stability test The physical stability of 5% PT-NLPs was evaluated by using a LUMiSizer® 651 stability analyzer, by recording the light transmission direction through the entire sample within a preselected time and the detectable attenuation of the incident light to quantify the change in the concentration of locally dispersed particles. About 15 mL of the sample of nanoliposome preparation 1 prepared on the first day was injected into the bottom of the nanocolloid stability test tube. The temperature of the predicted high-temperature six-month system stability test group (hereinafter referred to as the high-temperature short-term group) was set to 45 ℃, the accelerated centrifugal rotation speed was 4000 rpm / min, the sample transmission light characteristics were recorded every 30 s, and the total measurement time was 2 h. The temperature of the predicted normal temperature two-year system stability test group (hereinafter referred to as the normal temperature long-term group) was set to 25 ℃, the accelerated centrifugal rotation speed was 4000 rpm / min, the sample transmission light characteristics were recorded every 30 s, and the total measurement time was 8 h. The software was used to draw a curve of the change of the instability coefficient over time to indicate the instability state of the sample during high-speed centrifugation. The larger the instability coefficient, the more drastic the change, indicating that the physical stability of the sample during the storage period is worse. Results are shown in Figure 4 ,in Figure 4 A in the figure is the Lumisizer stability test result of the nanoliposome preparation 1 sample in the high temperature short-term group. Figure 4 B in the figure is the Lumisizer stability test result of the nanoliposome preparation 1 sample at room temperature and for a long time.

[0032] Test Example 2: Determination of 4-butylresorcinol content in nanoliposome preparations 1-7 Curve establishment: High performance liquid chromatography (HPLC) was used to determine the content of 4-butylresorcinol. 18 Column (4.6mm×250mm, 5µm); Column temperature: 30℃, Detection wavelength: 280nm, Mobile phase: 50% acetonitrile-50% standard sodium phosphate buffer solution, Flow rate: 1.0mL / min; Injection volume: 5µL; Procedure: Isocratic elution; Accurately weigh 0.1g (accurate to 0.00001g) of 4-butylresorcinol and place it in a 10mL volumetric flask, dilute with acetonitrile to prepare a 10g / L stock solution I for use. Take 0.05mL, 0.10mL, 0.2mL, 0.3mL, and 0.5mL of 10g / L 4-butylresorcinol standard solution in a 10mL volumetric flask, dilute with acetonitrile to prepare a series of standard solutions of 50µg / mL, 100µg / mL, 200µg / mL, 300µg / mL, and 500µg / mL, shake well, and set aside. According to the chromatographic conditions, the chromatogram of the standard substance is obtained, and the linear regression is performed with the peak area and the mass concentration of the sample as the vertical and horizontal coordinates to obtain the standard curve equation, and the linear range is 10-500 g / mL. In this patent, the encapsulation rate is calculated according to the following formula: Drug encapsulation rate (%) = amount of 4-butylresorcinol included / total amount of 4-butylresorcinol × 100%.

[0033] Determination of the amount of 4-butylresorcinol encapsulated: weigh 80 mg of 4-butylresorcinol liposome solution and pour it into a 10 mL centrifuge tube, add 6 mL of ultrapure water and oscillate and disperse evenly at room temperature. Place the centrifuge tube in a centrifuge and centrifuge at 3000 r / min for 5 minutes. Take 5 mL of supernatant and pre-freeze it in a -40°C refrigerator for 3 hours, and then place it in a freezer for drying. Take the freeze-dried powder and weigh it using a weighing bottle. Then, add the powder to 2 mL of acetonitrile and vortex for 1 minute to dissolve the membrane material, and then add 4 mL of acetonitrile and vortex for 1 minute to extract 4-butylresorcinol. Take 2 mL of n-hexane and add an equal amount of anhydrous ethanol for dilution, take 1 mL of the dilution and centrifuge it at 5000 r / min for 10 minutes. Finally, take 800 μL of the centrifugal supernatant and inject it into the injection bottle of the automatic HPLC to detect the content of 4-butylresorcinol. After conversion, the 4-butylresorcinol content (M1) contained in the unit mass of liposomes was calculated, and the amount of 4-butylresorcinol contained = M1 × the designed formula amount of the lecithin blank material. After being stored at room temperature for 12 months, the results of the determination of the 4-butylresorcinol content in the nanoliposome preparations 1-7 are shown in Table 4.

[0034] Table 4: Stability test results of nanoliposome preparations 1-7

[0035] As can be seen from the experimental results, the 4-butylresorcinol content in preparations 1 and 6 is stable, the 4-butylresorcinol damage in preparation 7 is the most serious, and the 4-butylresorcinol content in preparations 2-5 is more obviously reduced than that in preparations 1 and 6. Simultaneously, according to the shape observation of the nanoliposome preparation, the appearance of preparation 7 collapses seriously, while the appearance of preparations 1 and 6 is placed at room temperature for 12 months, and there is no obvious change in appearance, no granularity and stratification phenomenon, and no obvious change in particle size. The appearance of preparations 2-5 all collapses to varying degrees. Preparations 1 and 6 have good stability, so the liposome protective agent of the present invention can significantly increase the stability of nanoliposomes, and well protect the active ingredients wrapped in the nanoliposomes.

[0036] Test Example 3: Determination of astaxanthin content in nanoliposomes 8-14 The astaxanthin content was determined by high performance liquid chromatography (HPLC). 18 Column (4.6mm×250mm, 5µm); Column temperature: 30℃, Detection wavelength: 280nm, Mobile phase: 50% acetonitrile-50% buffer solution, Flow rate: 1.0mL / min; Injection volume: 5µL; Procedure: Isocratic elution; Accurately weigh 0.1g of astaxanthin (accurate to 0.00001g) and place it in a 10mL volumetric flask, dilute with acetonitrile to prepare a 10g / L stock solution I for use. Take 0.05mL, 0.10mL, 0.2mL, 0.3mL, and 0.5mL of 10g / L astaxanthin standard solution in a 10mL volumetric flask, dilute with acetonitrile to prepare a series of standard solutions of 50µg / mL, 100µg / mL, 200µg / mL, 300µg / mL, and 500µg / mL, shake well, and set aside. According to the chromatographic conditions, the chromatogram of the standard substance is obtained, and the linear regression is performed with the peak area and the mass concentration of the sample as the vertical and horizontal coordinates to obtain the standard curve equation. In this patent, the encapsulation rate is calculated according to the following formula: Drug encapsulation rate (%) = amount of astaxanthin included / total amount of astaxanthin × 100%.

[0037] Determination of the amount of astaxanthin included: weigh 80 mg of astaxanthin liposome solution and pour it into a 10 mL centrifuge tube, add 6 mL of ultrapure water and oscillate and disperse evenly at room temperature. Place the centrifuge tube in a centrifuge and centrifuge at 3000 r / min for 5 minutes. Take 5 mL of supernatant and pre-freeze it in a -40 ° C refrigerator for 3 hours, and then place it in a freezer for drying. Take the freeze-dried powder and weigh it using a weighing bottle. Then, add the powder to 2 mL of acetonitrile and vortex for 1 minute to dissolve the membrane material, and then add 4 mL of acetonitrile and vortex for 1 minute to extract astaxanthin. Take 2 mL of n-hexane and add an equal amount of anhydrous ethanol for dilution, take 1 mL of the dilution and centrifuge it at 5000 r / min for 10 minutes. Finally, take 800 μL of the centrifugal supernatant and inject it into the injection bottle of the automatic HPLC for astaxanthin content detection. After conversion, the astaxanthin (M1) contained in the unit mass of liposomes was calculated, and the amount of astaxanthin contained = M1 × the designed formula amount of the phospholipid blank material. After being stored at room temperature for 12 months, the astaxanthin content in the nanoliposome preparations 8-14 was determined as shown in Table 5.

[0038] Table 5: Stability test results of nanoliposome preparations 8-14

[0039] As can be seen from the experimental results, the astaxanthin content in preparations 8 and 13 is stable, the astaxanthin in preparation 14 is the most severely damaged, and the astaxanthin content in preparations 9-12 is more significantly reduced than that in preparations 8 and 13. At the same time, according to the shape of the nanoliposome preparation, the appearance of preparation 14 collapses seriously, while the appearance of preparations 8 and 13 is placed at room temperature for 12 months, and there is no obvious change in appearance, no granularity and stratification phenomenon, and no obvious change in particle size. The appearance of preparations 9-12 all collapses to varying degrees. Preparations 8 and 13 have good stability, so the liposome protective agent of the present invention can significantly increase the stability of nanoliposomes and well protect the active ingredients encapsulated in the nanoliposomes.

[0040] Test Example 4: Transdermal Test The treated suckling pig skin was fixed on the Frank diffusion cell, PBS buffer (PH = 7.4) was added to the receiving cell, and preparations 1-7 were added to the donor chamber. The mixture was placed in a 37°C constant temperature water bath and heated at 300 r·min. -1 Stirring, taking the receiving solution at 0.5h, 1h, 2h, 4h, 6h, 8h, 12h, 24h, and 48h, and supplementing with an equal amount of PBS, diluting the receiving solution 10 times with the mobile phase, and analyzing by the high performance liquid chromatography method in Test Example 1 to determine the content of 4-butylresorcinol, and calculating the cumulative transdermal permeation amount. The results are shown in Table 6.

[0041] Table 6: Transdermal test results of formulations 1-7

[0042] The experimental results show that the cumulative permeation of 4-butylresorcinol in preparations 1 and 6 in 48 hours is significantly higher than that in preparations 2-5, and more significantly higher than that in preparation 7. Therefore, the liposome protective agent of the present invention can enhance the transdermal performance of the nanoliposome system.

Claims

1. A nanoliposome protective agent with anti-ultraviolet and anti-oxidation functions, characterized in that: The nanoliposome protective agent comprises the following components: benzotriazolyl dodecyl p-cresol / benzotriazolyl butylphenol sodium sulfonate, tris(tetramethylhydroxypiperidinol) citrate, troxerutin / rutin and pentaerythritol tetra(di-tert-butylhydroxyhydrocinnamic acid) ester / tocopherol acetate.

2. The nanoliposome protective agent according to claim 1, characterized in that The components are composed by weight: 0.05-0.2 parts of benzotriazolyl dodecyl p-cresol / benzotriazolyl butylphenol sodium sulfonate, 0.05-0.2 parts of tris (tetramethyl hydroxypiperidinol) citrate, 0.15-0.6 parts of troxerutin / rutin and 0.05-0.2 parts of pentaerythritol tetra (di-tert-butyl hydroxyhydrocinnamate) ester / tocopherol acetate.

3. The nanoliposome protective agent according to claim 2, characterized in that The components are composed by weight: 0.1 part of benzotriazolyl dodecyl p-cresol / benzotriazolyl butylphenol sodium sulfonate, 0.15 part of tris (tetramethyl hydroxypiperidinol) citrate, 0.3 part of troxerutin / rutin and 0.1 part of pentaerythritol tetra (di-tert-butyl hydroxyhydrocinnamate) ester / tocopherol acetate.

4. A method for preparing the nanoliposome protective agent according to any one of claims 1 to 3, characterized in that: The preparation method of the nanoliposome protective agent is as follows: dissolving benzotriazolyl dodecyl p-cresol / benzotriazolyl butylphenol sodium sulfonate, tris(tetramethylhydroxypiperidinol) citrate, troxerutin / rutin and pentaerythritol tetra(di-tert-butyl hydroxyhydrocinnamate) ester / tocopherol acetate in a propylene glycol solvent, and homogenizing to obtain the protective agent.

5. The preparation method according to claim 4, characterized in that: The homogenization includes mixing shearing homogenization and homogenization by a microfluidizer.

6. The preparation method according to claim 4, characterized in that: The mixing shear pressure is 12000rpm-16000rpm, and the mixing shear homogenization time is 5-15min; the microfluidization homogenization pressure is 12000psi-20000psi, and the homogenization times are 1-3 times.

7. A nanoliposome preparation containing the nanoliposome protective agent according to any one of claims 1 to 3 or the nanoliposome protective agent prepared by the preparation method according to any one of claims 4 to 6.

8. The nanoliposome preparation according to claim 7, characterized in that The nanoliposome preparation comprises the following preparation steps: (1) dissolving benzotriazolyl dodecyl p-cresol / benzotriazolyl butylphenol sodium sulfonate, tris(tetramethylhydroxypiperidinol) citrate, troxerutin / rutin and pentaerythritol tetra(di-tert-butylhydroxyhydrocinnamate) ester / tocopherol acetate in propylene glycol solvent, homogenizing, and obtaining an alcohol phase; (2) shearing and homogenizing the oil phase and water phase of the liposome and the alcohol phase of step (1) to obtain a mixed colostrum; (3) The colostrum mixture is homogenized once by a microfluidizer.

9. The nanoliposome preparation according to claim 8, characterized in that The microfluidic homogenization pressure in step (3) is 12000psi-20000psi, and the homogenization times are 1-3 times.

10. Use of the nanoliposome protective agent according to any one of claims 1 to 3, or the nanoliposome protective agent prepared according to the preparation method according to any one of claims 4 to 6, or the nanoliposome preparation according to any one of claims 7 to 9 in the preparation of cosmetics with anti-ultraviolet and anti-oxidation functions.

Citation Information

Patent Citations

  • Chitosan-modified multivitamin nano-liposome as well as preparation method and application thereof in cosmetics

    CN112006924A

  • Triazine derivatives

    CN101443319A

  • Bicontinuous-phase thorough cleansing oil and preparation method thereof

    CN112057406A

  • Whitening co-loaded ionic liquid type liposome and preparation method thereof

    CN114533568A

  • Oily retinol derivative gel bead, skin care composition containing oily gel bead and preparation method of oily retinol derivative gel bead

    CN114617780A

Cited By

  • Composition for improving stability of 4-butylresorcinol, application of composition and external skin preparation

    CN119792107A